Basic Information
| RNALocate ID: | RLID:11002393 |
| RNA Symbol: | hsa-miR-130b-3p |
| Localization: | Extracellular vesicle |
RNA Information
| RNA Name: | hsa-miR-130b |
| RNA ID: | miRBase:MIMAT0000691 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 22849433 |
| Tissue/Cell Line: | HEK-293T cells |
| Method: | Next-generation RNA sequencing |
| Description: | The total numbers of reads >15 bp matching each miRNA were calculated. These values were then normalized to number of reads per million mapped (RPMM) in each library, to enable direct comparison of expression levels. As a measure of the relative levels of expression of individual miRNAs in cells and EVs, the log (base two) of the ratio of the read number in EVs over that in cells was calculated (log2 (EV/cell)). The miRNA expression data for cells and EVs is presented in Additional file 1: Table S1. Data are collected from Table S1. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01002002 | Mitochondrion | Skeletal muscle myoblasts | 21637849 |
| RLID:01002003 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:11002385 | Exosome | Pooled sera | 27278097 |
| RLID:11002386 | Exosome | HCC tissues | 30542726 |
| RLID:11002387 | Exosome | Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11002388 | Exosome | Renal cancer cells | 21670082 |
| RLID:11002389 | Exosome | Brain tissue | 23382797 |
| RLID:11002390 | Exosome | Plasma | 23663360 |
| RLID:11002391 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11002392 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11002394 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000114 | Exosome | B lymphoblastoid cells|Endothelial cells|Kidney tissue|Lymphoma tissue | |
| RLID-D:11000403 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-130b-3p | Idiopathic pulmonary fibrosis | MNDR-E-MI-10892 |
| MNDR | hsa-miR-130b-3p | Splenic marginal zone lymphoma | MNDR-E-MI-10893 |
| MNDR | hsa-miR-130b-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-10894 |
| MNDR | hsa-miR-130b-3p | Oral squamous cell carcinoma | MNDR-E-MI-10895 |
| MNDR | hsa-miR-130b-3p | Large cell neuroendocrine cancer | MNDR-E-MI-10896 |
| MNDR | hsa-miR-130b-3p | Medulloblastoma | MNDR-E-MI-10897 |
| MNDR | hsa-miR-130b-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-10898 |
| MNDR | hsa-miR-130b-3p | Ovarian clear cell carcinoma | MNDR-E-MI-10899 |
| MNDR | hsa-miR-130b-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-10900 |
| MNDR | hsa-miR-130b-3p | Lymphoma | MNDR-E-MI-10901 |
| MNDR | hsa-miR-130b-3p | Lymphoma non-hodgkin | MNDR-E-MI-10902 |
| MNDR | hsa-miR-130b-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-10903 |
| MNDR | hsa-miR-130b-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-10904 |
| MNDR | hsa-miR-130b-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-10905 |
| MNDR | hsa-miR-130b-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-10906 |
| MNDR | hsa-miR-130b-3p | Her2-receptor positive breast cancer | MNDR-E-MI-10907 |
| MNDR | hsa-miR-130b-3p | Breast cancer luminal | MNDR-E-MI-10908 |
| MNDR | hsa-miR-130b-3p | Niemann-pick disease type c | MNDR-E-MI-10909 |
| MNDR | hsa-miR-130b-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-10910 |
| MNDR | hsa-miR-130b-3p | Lupus nephritis | MNDR-E-MI-10911 |
| MNDR | hsa-miR-130b-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-10912 |
| MNDR | hsa-miR-130b-3p | Prostate cancer | MNDR-E-MI-10913 |
| MNDR | hsa-miR-130b-3p | Gastric cancer | MNDR-E-MI-10914 |
| MNDR | hsa-miR-130b-3p | Alzheimer disease | MNDR-E-MI-10915 |
| MNDR | hsa-miR-130b-3p | Intracranial aneurysm | MNDR-E-MI-10916 |
| MNDR | hsa-miR-130b-3p | Bladder cancer | MNDR-E-MI-10917 |
| MNDR | hsa-miR-130b-3p | Esophageal carcinoma | MNDR-E-MI-10918 |
| MNDR | hsa-miR-130b-3p | Dysautonomia familial | MNDR-E-MI-10919 |
| MNDR | hsa-miR-130b-3p | Head and neck cancer | MNDR-E-MI-10920 |
| MNDR | hsa-miR-130b-3p | Leukemia | MNDR-E-MI-10921 |
| MNDR | hsa-miR-130b-3p | Huntington disease | MNDR-E-MI-10922 |
| MNDR | hsa-miR-130b-3p | Cardiovascular disease | MNDR-E-MI-10923 |
| MNDR | hsa-miR-130b-3p | Carotid stenosis | MNDR-E-MI-10924 |
| MNDR | hsa-miR-130b-3p | Lung cancer | MNDR-E-MI-10925 |
| MNDR | hsa-miR-130b-3p | Endometrial cancer | MNDR-E-MI-10926 |
| MNDR | hsa-miR-130b-3p | Parkinson disease | MNDR-E-MI-10927 |
| MNDR | hsa-miR-130b-3p | Niemann-pick disease | MNDR-E-MI-10928 |
| MNDR | hsa-miR-130b-3p | Basal-like breast cancer | MNDR-E-MI-10929 |
| MNDR | hsa-miR-130b-3p | Pituitary neoplasms | MNDR-E-MI-10930 |
| MNDR | hsa-miR-130b-3p | Pancreatic cancer | MNDR-E-MI-10931 |
| MNDR | hsa-miR-130b-3p | Melanoma | MNDR-E-MI-10932 |
| MNDR | hsa-miR-130b-3p | Rectum adenocarcinoma | MNDR-E-MI-10933 |
| MNDR | hsa-miR-130b-3p | Nephroblastoma | MNDR-E-MI-10934 |
| MNDR | hsa-miR-130b-3p | Colon cancer | MNDR-E-MI-10935 |
| MNDR | hsa-miR-130b-3p | Ischemic attack transient | MNDR-E-MI-10936 |
| MNDR | hsa-miR-130b-3p | Colon adenocarcinoma | MNDR-E-MI-10937 |
| MNDR | hsa-miR-130b-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-10938 |
| MNDR | hsa-miR-130b-3p | Ovarian cancer | MNDR-E-MI-10939 |
| MNDR | hsa-miR-130b-3p | Prostate adenocarcinoma | MNDR-E-MI-10940 |
| MNDR | hsa-miR-130b-3p | Carcinoma ductal breast | MNDR-E-MI-10941 |
| MNDR | hsa-miR-130b-3p | Glioblastoma | MNDR-E-MI-10942 |
| MNDR | hsa-miR-130b-3p | Glioma | MNDR-E-MI-10943 |
| MNDR | hsa-miR-130b-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-10944 |
| MNDR | hsa-miR-130b-3p | Epilepsy temporal lobe | MNDR-E-MI-10945 |
| MNDR | hsa-miR-130b-3p | Osteosarcoma | MNDR-E-MI-10946 |
| MNDR | hsa-miR-130b-3p | Breast carcinoma | MNDR-E-MI-10947 |
| MNDR | hsa-miR-130b-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-10948 |
| MNDR | hsa-miR-130b-3p | Uterine cancer | MNDR-E-MI-10949 |
| MNDR | hsa-miR-130b-3p | Gastric adenocarcinoma | MNDR-E-MI-10950 |
| MNDR | hsa-miR-130b-3p | Cervical squamous cell carcinoma | MNDR-E-MI-10951 |
| MNDR | hsa-miR-130b-3p | Bone-invasive pituitary adenoma | MNDR-E-MI-10952 |
| MNDR | hsa-miR-130b-3p | Lung squamous cell carcinoma | MNDR-E-MI-10953 |
| MNDR | hsa-miR-130b-3p | Carcinoma lung non-small-cell | MNDR-E-MI-10954 |
| MNDR | hsa-miR-130b-3p | Lung adenocarcinoma | MNDR-E-MI-10955 |
| MNDR | hsa-miR-130b-3p | Adrenocortical carcinoma | MNDR-E-MI-10956 |
| MNDR | hsa-miR-130b-3p | Thyroid carcinoma | MNDR-E-MI-10957 |
| MNDR | hsa-miR-130b-3p | Ovarian carcinoma | MNDR-E-MI-10958 |
| MNDR | hsa-miR-130b-3p | Bladder urothelial carcinoma | MNDR-E-MI-10959 |
| MNDR | hsa-miR-130b-3p | Pancreatic adenocarcinoma | MNDR-E-MI-10960 |
| MNDR | hsa-miR-130b-3p | Systemic scleroderma | MNDR-E-MI-10961 |
| MNDR | hsa-miR-130b-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-10962 |
| MNDR | hsa-miR-130b-3p | Carcinoma renal cell | MNDR-E-MI-10963 |
| MNDR | hsa-miR-130b-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-10964 |
| MNDR | hsa-miR-130b-3p | Clear cell renal cell carcinoma | MNDR-E-MI-10965 |
| MNDR | hsa-miR-130b-3p | Large cell carcinoma | MNDR-E-MI-10966 |
| MNDR | hsa-miR-130b-3p | Biliary tract cancer | MNDR-E-MI-10967 |
| MNDR | hsa-miR-130b-3p | Cholangiocarcinoma | MNDR-E-MI-10968 |
| MNDR | hsa-miR-130b-3p | Esophageal cancer | MNDR-E-MI-10969 |
| MNDR | hsa-miR-130b-3p | Lung small cell carcinoma | MNDR-E-MI-10970 |
| MNDR | hsa-miR-130b-3p | Synovial sarcoma | MNDR-E-MI-10971 |
| MNDR | hsa-miR-130b-3p | Stomach carcinoma | MNDR-E-MI-10972 |
| MNDR | hsa-miR-130b-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-10973 |
| MNDR | hsa-miR-130b-3p | Testicular germ cell cancer | MNDR-E-MI-10974 |
| MNDR | hsa-miR-130b-3p | T acute lymphoblastic leukemia | MNDR-E-MI-10975 |
| MNDR | hsa-miR-130b-3p | Acute t cell leukemia | MNDR-E-MI-10976 |
| MNDR | hsa-miR-130b-3p | Fibromyalgia | MNDR-E-MI-10977 |
| MNDR | hsa-miR-130b-3p | Breast invasive carcinoma | MNDR-E-MI-10978 |
| MNDR | hsa-miR-130b-3p | Hepatocellular carcinoma | MNDR-E-MI-10979 |
| MNDR | hsa-miR-130b-3p | B-cell lymphoma | MNDR-E-MI-10980 |
| MNDR | hsa-miR-130b-3p | Rheumatoid arthritis | MNDR-E-MI-10981 |
| MNDR | hsa-miR-130b-3p | T-cell leukemia | MNDR-E-MI-10982 |
| MNDR | hsa-miR-130b-3p | Hodgkin lymphoma | MNDR-E-MI-10983 |
| MNDR | hsa-miR-130b-3p | Burkitt lymphoma | MNDR-E-MI-10984 |
| MNDR | hsa-miR-130b-3p | Dementia vascular | MNDR-E-MI-10985 |
| MNDR | hsa-miR-130b-3p | Neuromyelitis optica | MNDR-E-MI-10986 |
| MNDR | hsa-miR-130b-3p | Skin cutaneous melanoma | MNDR-E-MI-10987 |
| MNDR | hsa-miR-130b-3p | Skin melanoma | MNDR-E-MI-10988 |
| MNDR | hsa-miR-130b-3p | Acute myelogenous leukemia | MNDR-E-MI-10989 |
| MNDR | hsa-miR-130b-3p | Colorectal cancer | MNDR-E-MI-10990 |
| MNDR | hsa-miR-130b-3p | Multiple myeloma | MNDR-E-MI-10991 |
| MNDR | hsa-miR-130b-3p | Ovarian epithelial cancer | MNDR-E-MI-10992 |
| MNDR | hsa-miR-130b-3p | Diabetic nephropathies | MNDR-E-MI-10993 |
| MNDR | hsa-miR-130b-3p | Ependymoma | MNDR-E-MI-10994 |
| MNDR | hsa-miR-130b-3p | Prostatic neoplasms | MNDR-E-MI-10995 |
| MNDR | hsa-miR-130b-3p | Epstein-barr virus infections | MNDR-E-MI-10996 |
| MNDR | hsa-miR-130b-3p | Stroke lacunar | MNDR-E-MI-10997 |
| MNDR | hsa-miR-130b-3p | Breast cancer her3+ negative | MNDR-E-MI-10998 |
| MNDR | hsa-miR-130b-3p | Duke A | MNDR-E-MI-10999 |
| MNDR | hsa-miR-130b-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-11000 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ACVR1 | Homo sapiens | RR00038728 |
TOP